SEC Company Response from Ovid Therapeutics Inc. (OVID) (CIK 0001636651) (OVID) — May 2, 2017
Ovid Therapeutics Inc. (OVID) (CIK 0001636651)
Date: May 2, 2017 · CIK: 0001636651 · Accession: 0001193125-17-153906
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-217245
Letter
Re:
VIA EDGAR
May 2, 2017
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Suzanne Hayes
Ovid Therapeutics Inc.
Registration Statement on Form S-1
File No. 333-217245
Acceleration Request
Requested Date: May 4, 2017
Requested Time: 4:00 P.M. Eastern Daylight Time
Ladies and Gentleman:
In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Citigroup Global Markets Inc. and Cowen and Company, LLC, as representatives of the several underwriters, hereby join Ovid Therapeutics Inc. in requesting that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-217245) to become effective on May 4, 2017, at 4:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter.
Additionally, pursuant to Rule 460 of the Act, we hereby advise you that approximately 750 copies of the Preliminary Prospectus, dated April 25, 2017, were distributed by us, as representatives of the several underwriters, through the date hereof:
We will comply, and have been informed by the participating underwriters that they will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.
Very truly yours,
CITIGROUP GLOBAL MARKETS INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP VIA EDGAR May 2, 2017 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Suzanne Hayes Re: Ovid Therapeutics Inc. Registration Statement on Form S-1 File No. 333-217245 Acceleration Request Requested Date: May 4, 2017 Requested Time: 4:00 P.M. Eastern Daylight Time Ladies and Gentleman: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Citigroup Global Markets Inc. and Cowen and Company, LLC, as representatives of the several underwriters, hereby join Ovid Therapeutics Inc. in requesting that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-217245) to become effective on May 4, 2017, at 4:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter. Additionally, pursuant to Rule 460 of the Act, we hereby advise you that approximately 750 copies of the Preliminary Prospectus, dated April 25, 2017, were distributed by us, as representatives of the several underwriters, through the date hereof: We will comply, and have been informed by the participating underwriters that they will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable. Very truly yours, CITIGROUP GLOBAL MARKETS INC. By: /s/ Brian Gleason Name: Brian Gleason Title: Managing Director COWEN AND COMPANY, LLC By: /s/ Jason Fenton Name: Jason Fenton Title: Managing Director cc: Mitchell S. Bloom, Goodwin Procter LLP Edwin O’Connor, Goodwin Procter LLP Seo Salimi, Goodwin Procter LLP Yaron Werber, Ovid Therapeutics Inc. Laura A. Berezin, Cooley LLP Divakar Gupta, Cooley LLP Robert W. Phillips, Cooley LLP Jaime L. Chase, Cooley LLP